Phaseline

Companies › OHB Pediatrics

OHB Pediatrics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rugonersen
UBE3A antisense oligonucleotide
UBE3APhase 3Angelman SyndromeMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07605429rugonersenPhase 3Angelman SyndromeOtherMar 2029

Targets

UBE3A (1)

Companies with the same targets

MavriX Bio Ionis Pharmaceuticals Ultragenyx Pharmaceutical

Companies built like this

Aesculap Biologics Metcela CoNextions Medical ULURU DiscGenics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.